MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine

Схожие документы

• Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes
  по: Breccia, Massimo, et al.
  Опубликовано: (2011)
• Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome
  по: Molica, Matteo, et al.
  Опубликовано: (2014)
• Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.
  по: Breccia, Massimo, et al.
  Опубликовано: (2011)
• The role of azacitidine in the management of myelodysplastic syndromes (MDS)
  по: Götze, KS, et al.
  Опубликовано: (2009)
• Systematic review of dasatinib in chronic myeloid leukemia
  по: Breccia, Massimo, et al.
  Опубликовано: (2013)